Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update
Werewolf Therapeutics stock traded near 45 cents Monday morning, holding close to its 52-week low on Nasdaq. Investors watching for updates on the company’s ongoing strategic review. Shares were flat in early trading, putting the company’s market cap near $22 million. The timing here is important because the most recent company-specific filing before this week wasn’t a trial update—it was an insider sale. A Form 4 filed after the bell Friday showed entities tied to director Luke Evnin dumped a total of 141,106 Werewolf shares between May 27 and May 29, using a Rule 10b5-1 plan, which lets insiders sell stock on a schedule.